{"id":57587,"date":"2026-06-04T21:36:17","date_gmt":"2026-06-04T12:36:17","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4579\/"},"modified":"2026-08-23T13:59:35","modified_gmt":"2026-08-23T04:59:35","slug":"company-4579","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4579\/","title":{"rendered":"RAQUALIA PHARMA INC"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4579","DATE":"2026-01-09","longName":"RaQualia Pharma Inc.","company_name_ja":"","fullTimeEmployees":85,"address":"","phone":"","website":"https:\/\/www.raqualia.com","industry":"Biotechnology","sector":"Healthcare","regularMarketPrice":1019,"financialCurrency":"","marketCap":24922,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":3979956000,"OperatingIncome":483720000,"operatingMargins":12.15,"NetIncome":273115000,"profitMargins":6.8600000000000003,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":3.96,"recommendationMean":0,"recommendationKey":"none","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T04:19:07.442101\", \"ticker\": \"4579\", \"ticker_full\": \"4579.T\", \"company_name\": \"RAQUALIA PHARMA INC\", \"analyst_recommendations\": {\"has_data\": true, \"recommendation_key\": \"none\", \"recommendation_mean\": null, \"total_analysts\": null, \"strong_buy\": null, \"buy\": null, \"hold\": null, \"sell\": null, \"strong_sell\": null}, \"target_prices\": {\"has_data\": true, \"current\": 482.0, \"high\": null, \"low\": null, \"mean\": null, \"median\": null}, \"earnings_dates\": {\"has_data\": false}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 31.88, \"institution_pct\": 1.87, \"major_holders\": [{\"label\": \"\", \"value\": 31.88}, {\"label\": \"\", \"value\": 1.87}, {\"label\": \"\", \"value\": 2.75}, {\"label\": \"\", \"value\": 3.0}], \"institutional_holders\": [], \"mutualfund_holders\": []}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. The company human products portfolio includes tegoprazan for gastroesophageal reflux disease; and grapiprant for cancer and pain management; RQ-00000008 for the treatment of osteoarthritis autoimmune disorders; RQ-00000010 to treat gastroparesis. It also provides veterinary products, such as capromorelin to treat anorexia in dogs and weight management in cats; grapiprant for osteoarthritis in dogs; RQ-00000008 to treat osteoarthritis and others; RQ-00317076 for pain; and RQ-00000010 for gut motility disorders, gastroparesis, functional dyspepsia, and chronic constipation. In addition, it provides RQ-00433412 for constipation, and cancer-related anorexia\/cachexia syndrome; RQ-00000009 to treat alzheimer's; RQ-00466479, RQ-00350215, and RQ-00434739 to treat chronic pain; RQ-00310941 to treat D-IBS, IBD-remission stage symptoms; RQ-00201894 for gastroparesis, functional dyspepsia, and post-operative ileus; tamibarotene to treat higher-risk myelodysplastic syndrome and acute myeloid leukemia; and FIM-001 for cancer. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T02:25:35.456166\", \"ticker\": \"4579\", \"ticker_full\": \"4579.T\", \"company_name\": \"RAQUALIA PHARMA INC\", \"company_info\": {\"name_en\": \"RAQUALIA PHARMA INC\", \"long_name\": \"RaQualia Pharma Inc.\", \"sector\": \"Healthcare\", \"industry\": \"Biotechnology\", \"website\": \"https:\/\/www.raqualia.com\", \"employees\": 85, \"country\": \"Japan\", \"city\": \"Nagoya\", \"address\": \"Meieki Southside Square\", \"description\": \"RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. The company human products portfolio includes tegoprazan for gastroesophageal reflux disease; and grapiprant for cancer and pain management; RQ-00000008 for the treatment of osteoarthritis autoimmune disorders; RQ-00000010 to treat gastroparesis. It also provides veterinary products, such as capromorelin to treat anorexia in dogs and weight management in cats; grapiprant for osteoarthritis in dogs; RQ-00000008 to treat osteoarthritis and others; RQ-00317076 for pain; and RQ-00000010 for gut motility disorders, gastroparesis, functional dyspepsia, and chronic constipation. In addition, it provides RQ-00433412 for constipation, and cancer-related anorexia\/cachexia syndrome; RQ-00000009 to treat alzheimer's; RQ-00466479, RQ-00350215, and RQ-00434739 to treat chronic pain; RQ-00310941 to treat D-IBS, IBD-remission stage symptoms; RQ-00201894 for gastroparesis, functional dyspepsia, and post-operative ileus; tamibarotene to treat higher-risk myelodysplastic syndrome and acute myeloid leukemia; and FIM-001 for cancer. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 559.2, \"deviation\": 1.04, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 496.76, \"deviation\": 13.74, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 523.59, \"deviation\": 7.91, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 761.8, \"deviation\": -25.83, \"trend\": \"down\"}}, \"financials\": {\"years\": [{\"year\": 2025, \"revenue\": 3979956000.0, \"revenue_fmt\": \"\u00a540\u5104\", \"gross_profit\": 3268003000.0, \"gross_profit_fmt\": \"\u00a533\u5104\", \"operating_income\": 483720000.0, \"operating_income_fmt\": \"\u00a55\u5104\", \"ebit\": 497005000.0, \"ebit_fmt\": \"\u00a55\u5104\", \"net_income\": 273115000.0, \"net_income_fmt\": \"\u00a53\u5104\", \"eps\": 0, \"operating_margin\": 12.15, \"total_assets\": 10514193000.0, \"total_assets_fmt\": \"\u00a5105\u5104\", \"total_equity\": 6896262000.0, \"total_equity_fmt\": \"\u00a569\u5104\", \"total_debt\": 2901892000.0, \"total_debt_fmt\": \"\u00a529\u5104\", \"total_cash\": 3240965000.0, \"total_cash_fmt\": \"\u00a532\u5104\", \"equity_ratio\": 65.59, \"de_ratio\": 0.42, \"current_ratio\": 4.46, \"operating_cf\": -354426000.0, \"operating_cf_fmt\": \"-\u00a54\u5104\", \"investing_cf\": 124321000.0, \"investing_cf_fmt\": \"\u00a51\u5104\", \"financing_cf\": 378064000.0, \"financing_cf_fmt\": \"\u00a54\u5104\", \"free_cf\": -429094000.0, \"free_cf_fmt\": \"-\u00a54\u5104\", \"net_margin\": 6.86, \"roe\": 3.96, \"roa\": 2.6}, {\"year\": 2024, \"revenue\": 3107575000.0, \"revenue_fmt\": \"\u00a531\u5104\", \"gross_profit\": 2481816000.0, \"gross_profit_fmt\": \"\u00a525\u5104\", \"operating_income\": -213382000.0, \"operating_income_fmt\": \"-\u00a52\u5104\", \"ebit\": -315117000.0, \"ebit_fmt\": \"-\u00a53\u5104\", \"net_income\": -495031000.0, \"net_income_fmt\": \"-\u00a55\u5104\", \"eps\": -22.87, \"operating_margin\": -6.87, \"total_assets\": 9655482000.0, \"total_assets_fmt\": \"\u00a597\u5104\", \"total_equity\": 5570510000.0, \"total_equity_fmt\": \"\u00a556\u5104\", \"total_debt\": 3452334000.0, \"total_debt_fmt\": \"\u00a535\u5104\", \"total_cash\": 3340057000.0, \"total_cash_fmt\": \"\u00a533\u5104\", \"equity_ratio\": 57.69, \"de_ratio\": 0.62, \"current_ratio\": 3.82, \"operating_cf\": 180945000.0, \"operating_cf_fmt\": \"\u00a52\u5104\", \"investing_cf\": -3665610000.0, \"investing_cf_fmt\": \"-\u00a537\u5104\", \"financing_cf\": 2982105000.0, \"financing_cf_fmt\": \"\u00a530\u5104\", \"free_cf\": 65046000.0, \"free_cf_fmt\": \"\u00a565.0M\", \"net_margin\": -15.93, \"roe\": -8.89, \"roa\": -5.13}, {\"year\": 2023, \"revenue\": 1901202000.0, \"revenue_fmt\": \"\u00a519\u5104\", \"gross_profit\": 1656149000.0, \"gross_profit_fmt\": \"\u00a517\u5104\", \"operating_income\": -337365000.0, \"operating_income_fmt\": \"-\u00a53\u5104\", \"ebit\": -287368000.0, \"ebit_fmt\": \"-\u00a53\u5104\", \"net_income\": -323662000.0, \"net_income_fmt\": \"-\u00a53\u5104\", \"eps\": -14.98, \"operating_margin\": -17.74, \"total_assets\": 6871972000.0, \"total_assets_fmt\": \"\u00a569\u5104\", \"total_equity\": 6120442000.0, \"total_equity_fmt\": \"\u00a561\u5104\", \"total_debt\": 367718000.0, \"total_debt_fmt\": \"\u00a54\u5104\", \"total_cash\": 3714984000.0, \"total_cash_fmt\": \"\u00a537\u5104\", \"equity_ratio\": 89.06, \"de_ratio\": 0.06, \"current_ratio\": 12.73, \"operating_cf\": -718596000.0, \"operating_cf_fmt\": \"-\u00a57\u5104\", \"investing_cf\": -135373000.0, \"investing_cf_fmt\": \"-\u00a51\u5104\", \"financing_cf\": 793450000.0, \"financing_cf_fmt\": \"\u00a58\u5104\", \"free_cf\": -940801000.0, \"free_cf_fmt\": \"-\u00a59\u5104\", \"net_margin\": -17.02, \"roe\": -5.29, \"roa\": -4.71}, {\"year\": 2022, \"revenue\": 2918038000.0, \"revenue_fmt\": \"\u00a529\u5104\", \"gross_profit\": 2686452000.0, \"gross_profit_fmt\": \"\u00a527\u5104\", \"operating_income\": 866236000.0, \"operating_income_fmt\": \"\u00a59\u5104\", \"ebit\": 857006000.0, \"ebit_fmt\": \"\u00a59\u5104\", \"net_income\": 723390000.0, \"net_income_fmt\": \"\u00a57\u5104\", \"eps\": 34.47, \"operating_margin\": 29.69, \"total_assets\": 6257653000.0, \"total_assets_fmt\": \"\u00a563\u5104\", \"total_equity\": 5496980000.0, \"total_equity_fmt\": \"\u00a555\u5104\", \"total_debt\": 222338000.0, \"total_debt_fmt\": \"\u00a52\u5104\", \"total_cash\": 3675450000.0, \"total_cash_fmt\": \"\u00a537\u5104\", \"equity_ratio\": 87.84, \"de_ratio\": 0.04, \"current_ratio\": 9.77, \"operating_cf\": 1480084000.0, \"operating_cf_fmt\": \"\u00a515\u5104\", \"investing_cf\": -47649000.0, \"investing_cf_fmt\": \"-\u00a547.6M\", \"financing_cf\": -29563000.0, \"financing_cf_fmt\": \"-\u00a529.6M\", \"free_cf\": 1448179000.0, \"free_cf_fmt\": \"\u00a514\u5104\", \"net_margin\": 24.79, \"roe\": 13.16, \"roa\": 11.56}, {\"year\": 2021, \"revenue\": 0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": 0, \"operating_income_fmt\": \"N\/A\", \"ebit\": 0, \"ebit_fmt\": \"N\/A\", \"net_income\": 0, \"net_income_fmt\": \"N\/A\", \"eps\": 36.04, \"operating_margin\": 0, \"total_assets\": 0, \"total_assets_fmt\": \"N\/A\", \"total_equity\": 0, \"total_equity_fmt\": \"N\/A\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 0, \"total_cash_fmt\": \"N\/A\", \"equity_ratio\": 0, \"de_ratio\": 0, \"current_ratio\": 0, \"operating_cf\": 0, \"operating_cf_fmt\": \"N\/A\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 0, \"financing_cf_fmt\": \"N\/A\", \"free_cf\": 0, \"free_cf_fmt\": \"N\/A\", \"net_margin\": 0, \"roe\": 0, \"roa\": 0}], \"has_data\": true}, \"dividends\": {\"history\": [], \"has_data\": false}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-57587","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>RAQUALIA PHARMA INC - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4579\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4579\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4579\/\",\"name\":\"RAQUALIA PHARMA INC - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-04T12:36:17+00:00\",\"dateModified\":\"2026-08-23T04:59:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4579\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4579\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4579\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RAQUALIA PHARMA INC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RAQUALIA PHARMA INC - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4579\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4579\/","url":"https:\/\/japanir.jp\/en\/company\/company-4579\/","name":"RAQUALIA PHARMA INC - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-04T12:36:17+00:00","dateModified":"2026-08-23T04:59:35+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4579\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4579\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4579\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"RAQUALIA PHARMA INC"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/57587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=57587"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=57587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}